Synthesis and Anticancer Activity of Novel Dual Inhibitors of Human Protein Kinases CK2 and PIM-1

CK2 and PIM-1 are serine/threonine kinases involved in the regulation of many essential processes, such as proliferation, differentiation, and apoptosis. Inhibition of CK2 and PIM-1 kinase activity has been shown to significantly reduce the viability of cancer cells by inducing apoptosis. A series of novel amino alcohol derivatives of parental DMAT were designed and synthesized as potent dual CK2/PIM-1 inhibitors. Concomitantly with the inhibition studies toward recombinant CK2 and PIM-1, the influence of the obtained compounds on the viability of three human carcinoma cell lines, i.e., acute lymphoblastic leukemia (CCRF-CEM), human chronic myelogenous leukemia (K-562), and breast cancer (MCF-7), as well as non-cancerous cells (Vero), was evaluated using an MTT assay. Induction of apoptosis and cell cycle progression after treatment with the most active compound and a lead compound were studied by flow-cytometry-based assay. Additionally, autophagy induction in K-562 cells and intracellular inhibition of CK2 and PIM-1 in all the tested cell lines were evaluated by qualitative/quantitative fluorescence-based assay and Western blot method, respectively. Among the newly developed inhibitors, 1,1,1-trifluoro-3-[(4,5,6,7-tetrabromo-1H-benzimidazol-2-yl)amino]propan-2-ol demonstrates the highest selectivity and the most prominent proapoptotic properties towards the studied cancer cells, especially towards acute lymphoblastic leukemia, in addition to inducing autophagy in K-562 cells.

[1]  S. Cao,et al.  Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects. , 2023, Journal of medicinal chemistry.

[2]  Z. Kazimierczuk,et al.  Antitumor activity of the protein kinase inhibitor 1-(β-D-2′-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines , 2022, BMC Cancer.

[3]  B. Kren,et al.  Protein kinase CK2 – diverse roles in cancer cell biology and therapeutic promise , 2022, Molecular and Cellular Biochemistry.

[4]  Ravindra G. Kulkarni,et al.  Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives. , 2022, Biochimica et biophysica acta. Reviews on cancer.

[5]  R. Ostrowski,et al.  Inhibiting CK2 among Promising Therapeutic Strategies for Gliomas and Several Other Neoplasms , 2022, Pharmaceutics.

[6]  M. Rędowicz,et al.  Synthesis of Novel Acyl Derivatives of 3-(4,5,6,7-Tetrabromo-1H-benzimidazol-1-yl)propan-1-ols—Intracellular TBBi-Based CK2 Inhibitors with Proapoptotic Properties , 2021, International journal of molecular sciences.

[7]  D. Spring,et al.  Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study , 2021, Molecules.

[8]  M. Rędowicz,et al.  Synergistic Interactions of 5-Fluorouracil with Inhibitors of Protein Kinase CK2 Correlate with p38 MAPK Activation and FAK Inhibition in the Triple-Negative Breast Cancer Cell Line , 2020, International journal of molecular sciences.

[9]  A. Bhatt,et al.  Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin , 2019, Bioscience reports.

[10]  M. Ruzzene,et al.  Role of protein kinase CK2 in antitumor drug resistance , 2019, Journal of Experimental & Clinical Cancer Research.

[11]  M. Koronkiewicz,et al.  Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells , 2019, AntiCancer Research.

[12]  Sharad Kumar,et al.  Autophagy-dependent cell death , 2018, Cell Death & Differentiation.

[13]  K. Niefind,et al.  Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases. , 2018, Bioorganic chemistry.

[14]  M. Koronkiewicz,et al.  Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells , 2018, AntiCancer Research.

[15]  A. Ferguson,et al.  Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases. , 2018, Bioorganic & medicinal chemistry letters.

[16]  Z. Chilmonczyk,et al.  Deoxynucleosides with benzimidazoles as aglycone moiety are potent anticancer agents , 2018, European journal of pharmacology.

[17]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[18]  A. Kraft,et al.  Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents , 2017, Clinical Cancer Research.

[19]  S. Fox,et al.  Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer , 2017, Oncotarget.

[20]  G. Toffoli,et al.  Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer Cells , 2017, Journal of immunology research.

[21]  M. Wielechowska,et al.  Synthesis, in vitro antiproliferative activity and kinase profile of new benzimidazole and benzotriazole derivatives. , 2017, Bioorganic chemistry.

[22]  Marie-Claude Blatter,et al.  Drug Design Workshop: A Web-Based Educational Tool To Introduce Computer-Aided Drug Design to the General Public , 2017 .

[23]  R. Vogel,et al.  CK2 Molecular Targeting—Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer , 2017, Pharmaceuticals.

[24]  E. Filippi-Chiela,et al.  Ratiometric analysis of Acridine Orange staining in the study of acidic organelles and autophagy , 2016, Journal of Cell Science.

[25]  Bi-hua Tan,et al.  Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies. , 2016, Current pharmaceutical design.

[26]  Ailin Tao,et al.  Cell-in-Cell Death Is Not Restricted by Caspase-3 Deficiency in MCF-7 Cells , 2016, Journal of breast cancer.

[27]  M. Wielechowska,et al.  Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity. , 2016, Bioorganic & medicinal chemistry.

[28]  T. Tokay,et al.  Pim-1 kinase as cancer drug target: An update. , 2016, Biomedical reports.

[29]  R. Taulli,et al.  Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias , 2015, Advances in hematology.

[30]  M. Wielechowska,et al.  Synthesis of novel chiral TBBt derivatives with hydroxyl moiety. Studies on inhibition of human protein kinase CK2α and cytotoxicity properties. , 2014, European journal of medicinal chemistry.

[31]  C. Girardi,et al.  Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential , 2014, Cellular and Molecular Life Sciences.

[32]  Carmen Blanco-Aparicio,et al.  The PIM Family of Serine/Threonine Kinases in Cancer , 2014, Medicinal research reviews.

[33]  C. Girardi,et al.  Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases. , 2013, Biochimica et biophysica acta.

[34]  A. Ferguson,et al.  Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. , 2012, Bioorganic & medicinal chemistry letters.

[35]  J. Bain,et al.  ATP site-directed inhibitors of protein kinase CK2: an update. , 2011, Current topics in medicinal chemistry.

[36]  Stefan Knapp,et al.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers , 2010, Haematologica.

[37]  C. Van Waes,et al.  Emergence of protein kinase CK2 as a key target in cancer therapy , 2010, BioFactors.

[38]  O. Franco,et al.  Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma , 2010, Oncogene.

[39]  R. Zhao,et al.  Pim-1 plays a pivotal role in hypoxia-induced chemoresistance , 2009, Oncogene.

[40]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[41]  M. Dyer,et al.  Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. , 2009, The Journal of clinical investigation.

[42]  S. Shepard,et al.  Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. , 2009, Organic letters.

[43]  Jie-Hui Li,et al.  PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. , 2009, The Journal of clinical investigation.

[44]  M. Lilly,et al.  The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells* , 2008, Journal of Biological Chemistry.

[45]  F. Ringeisen,et al.  Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. , 2007, European journal of cancer.

[46]  J. Eble,et al.  Overexpression of Pim-1 during progression of prostatic adenocarcinoma , 2006, Journal of Clinical Pathology.

[47]  D. Mottet,et al.  Role for casein kinase 2 in the regulation of HIF‐1 activity , 2005, International journal of cancer.

[48]  G. Unger,et al.  Targeting CK2 for cancer therapy. , 2005, Anti-cancer drugs.

[49]  J. Houghton,et al.  Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines , 2005, Oncogene.

[50]  Jun Li,et al.  Structural Basis of Constitutive Activity and a Unique Nucleotide Binding Mode of Human Pim-1 Kinase* , 2005, Journal of Biological Chemistry.

[51]  P. Hammerman,et al.  Lymphocyte Transformation by Pim-2 Is Dependent on Nuclear Factor-κB Activation , 2004, Cancer Research.

[52]  J. Bain,et al.  Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. , 2004, Journal of medicinal chemistry.

[53]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[54]  L. Pinna,et al.  Protein kinase CK2 phosphorylates BAD at threonine-117 , 2004, Neurochemistry International.

[55]  P. Ekman,et al.  Pim‐1 expression in prostatic intraepithelial neoplasia and human prostate cancer , 2004, The Prostate.

[56]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[57]  A. Kraft,et al.  The PIM-2 Kinase Phosphorylates BAD on Serine 112 and Reverses BAD-induced Cell Death* , 2003, Journal of Biological Chemistry.

[58]  A. Brunati,et al.  Polyhalogenobenzimidazoles: synthesis and their inhibitory activity against casein kinases. , 2003, Bioorganic & medicinal chemistry.

[59]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[60]  D. Seldin,et al.  Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis , 2002, Oncogene.

[61]  Ying Li,et al.  AKT/PKB Phosphorylation of p21Cip/WAF1 Enhances Protein Stability of p21Cip/WAF1 and Promotes Cell Survival* , 2002, The Journal of Biological Chemistry.

[62]  R. Cardiff,et al.  Protein kinase CK2: Signaling and tumorigenesis in the mammary gland , 2001, Molecular and Cellular Biochemistry.

[63]  J. Hériché,et al.  Protein kinase CK2α is a target for the Abl and Bcr–Abl tyrosine kinases , 1998, Oncogene.

[64]  D. Schomburg,et al.  Crystal structure of the catalytic subunit of protein kinase CK2 from Zea mays at 2.1 Å resolution , 1998, The EMBO journal.

[65]  M. Itabashi,et al.  Expression of Bcl‐2 in human breast cancer: Correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosis , 1997, Pathology international.

[66]  J. Ellingboe,et al.  Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides. , 1992, Journal of medicinal chemistry.

[67]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[68]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.

[69]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.